Sat, Sep 20, 2014, 2:39 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Oncothyreon Inc Message Board

  • jyardagg jyardagg Nov 19, 2013 12:21 PM Flag

    they are still learning from ONT 10 P1, P1b

    The ONT 10 trial has produced safety and early efficacy results. However it is still ongoing with more patients to be enrolled. I have a theory that they will learn from the early responders and apply the techniques and doses that work be best Then, the phase 2 next year may just be an extension of p1, p1b with the multiple indications that may show to be the best targets. It may be multiple indications, ovarian, and another form, maybe lung and or others. They could fine tune it to get the best out of ONT 10 effectiveness.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.09-0.06(-2.79%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.